News & Videos - REGENERON PHARMACEUTICALS INC. - Page 2

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, today announced that it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals, Inc. Under the terms of the agreement, Xeris will use its proprietary drug-formulation platform, XeriJect™, to develop ultra-highly...

Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (T reg ) therapies for autoimmune diseases. The collaboration will bring together Regeneron’s industry-leading VelociSuite ® technologies for the discovery and characterization of fully human antibodies and T cell...

Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease PR Newswire TARRYTOWN, N.Y. and WASHINGTON, March 14, 2023 $250,000 top award goes to Neel Moudgal in the nation's oldest and most prestigious science and math competition for high school seniors TARRYTOWN, N.Y. and WASHINGTON , March 14, 2023 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society...

Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition PR Newswire TARRYTOWN, N.Y. and WASHINGTON, Jan. 24, 2023 Nation's Most Innovative Teens will Showcase Research with Prizes of Over $1.8 million TARRYTOWN, N.Y. and WASHINGTON , Jan. 24, 2023 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this...

2seventy bio, Inc. (Nasdaq: TSVT) today announced an amendment to its collaboration with Regeneron that will facilitate an expanded and accelerated development plan for novel cell therapy-based combinations for solid tumors. The collaboration will leverage 2seventy bio’s unique cell therapy engineering and early-stage development capabilities, including the newly built in-house clinical cell therapy manufacturing facility, with Regeneron’s differentiated antibodies and bispecifics....

Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer PR Newswire TARRYTOWN, N.Y., Dec. 23, 2022 TARRYTOWN, N.Y. , Dec. 23, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Libtayo ® (cemiplimab) as monotherapy to treat patients with advanced or recurrent cervical cancer whose disease progressed after chemotherapy. "In...

Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine PR Newswire TARRYTOWN, N.Y. and PARIS, Dec. 21, 2022 Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo Improvements were sustained for up to one year in patients aged 12 years and older with eosinophilic esophagitis (EoE) Dupixent is the first and only targeted...

Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire TARRYTOWN, N.Y., Dec. 19, 2022 TARRYTOWN, N.Y. , Dec. 19, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 . The presentation is scheduled for 9:00 a.m. Pacific Time ( 12:00 p.m. Eastern Time ) and may be accessed from the "Investors & Media" page of Regeneron's website...

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis PR Newswire TARRYTOWN, N.Y. and PARIS, Dec. 16, 2022 If approved, Dupixent would be the first and only targeted medicine specifically indicated for people aged 12 years and older with eosinophilic esophagitis in the European Union In the U.S., Dupixent is currently the only medicine indicated to treat eosinophilic esophagitis Approval recommendation based on pivotal trial data...

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis PR Newswire TARRYTOWN, N.Y. and PARIS, Dec. 15, 2022 Approval based on direct-to-Phase 3 program showing more than three times as many Dupixent patients (60% and 58%) experienced clinically meaningful itch reduction at 24 weeks compared to placebo (18% and 20%) Dupixent also significantly reduced skin lesions and improved health-related quality of life compared to...

Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial PR Newswire TARRYTOWN, N.Y., Dec. 12, 2022 First Phase 2 data presented at ASH showed an 82% response rate in patients with grades 1 to 3a disease, with 75% of the overall population achieving a complete response 20-month median progression-free survival, with median overall survival not reached Data will form the basis of regulatory...

Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma PR Newswire TARRYTOWN, N.Y., Dec. 12, 2022 As presented at ASH, recommended 200 mg dose of linvoseltamab demonstrated a 64% response rate, with 45% of responders achieving a very good partial response or better; responses may further improve with longer follow-up Trial enrolled patients with particularly high disease burden, with 37% having bone marrow...

Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year PR Newswire TARRYTOWN, N.Y., Dec. 12, 2022 DJSI World recognizes the top 10 percent of most sustainable companies by industry; Regeneron ranked among top three biotechnology companies 1 TARRYTOWN, N.Y. , Dec. 12, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the company has been included on the Dow Jones Sustainability World Index (DJSI World) for the fourth consecutive...

Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH PR Newswire TARRYTOWN, N.Y., Dec. 11, 2022 49% objective response rate ( ORR ) in heavily pre-treated patients who were naïve to prior CAR-T, with 31% achieving a complete response (CR) Even in patients who received prior CAR-T, 48% ORR and 32% CR observed in a dose expansion cohort from a Phase 1 trial Data will form the basis of regulatory submissions planned for 2023...

Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types PR Newswire TARRYTOWN, N.Y., Dec. 1, 2022 Presentations include initial results for an investigational combination of fianlimab (LAG-3 inhibitor) and Libtayo (PD-1 inhibitor) in advanced non-small cell lung cancer TARRYTOWN, N.Y. , Dec. 1, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data across its oncology pipeline will...

Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review PR Newswire TARRYTOWN, N.Y., Nov. 30, 2022 If approved, Evkeeza would be the first and only treatment of its kind to help children as young as 5 years old control dangerously high levels of LDL cholesterol caused by homozygous familial hypercholesterolemia TARRYTOWN, N.Y. , Nov. 30, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced...

Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology PR Newswire TARRYTOWN, N.Y., Nov. 22, 2022 Approval based on a Phase 3 trial that demonstrated significant survival benefit in patients with recurrent or metastatic cervical cancer, with Libtayo reducing the risk of death by 31% compared to chemotherapy during the study Libtayo now approved to treat...

Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer PR Newswire TARRYTOWN, N.Y. and SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX's Probody ® and Regeneron's Veloci-Bi ® platforms CytomX to receive $30 million upfront payment with the potential for up to $2 billion in research, development,...

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis PR Newswire TARRYTOWN, N.Y. and PARIS, Nov. 11, 2022 Recommendation is based on data from two pivotal trials showing Dupixent significantly improved itch, skin lesions and health-related quality of life in adults with prurigo nodularis If approved, Dupixent would be the first and only targeted medicine specifically indicated for prurigo nodularis in the European Union TARRYTOWN, N.Y. and PARIS ,...

Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) PR Newswire TARRYTOWN, N.Y., Nov. 8, 2022 Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide range of disease characteristics Second advanced NSCLC indication expands patient population eligible for a Libtayo-based regimen to include combination treatment...